DDI-DrugBank.d765.s0 >> CYP3A4 Inhibitors: Ketoconazole, an inhibitor of the drug metabolizing enzyme CYP3A4, significantly increased plasma concentrations of tolterodine when coadministered to subjects who were poor metabolizers (see CLINICAL PHARMACOLOGY, Variability in Metabolism and Drug-Drug Interactions). >> 19-30,135-145
DDI-DrugBank.d765.s1 >> For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. >> 23-34,84-100,107-118,121-130,136-156,163-174,177-190,196-207,212-222,249-257
DDI-DrugBank.d765.s2 >> Drug-Laboratory-Test Interactions Interactions between tolterodine and laboratory tests have not been studied. >> 55-65
